Unique ID issued by UMIN | UMIN000006273 |
---|---|
Receipt number | R000007427 |
Scientific Title | A phase I study of pemetrexed and gefitinib in chemotherapy naive elderly patients with non- small cell lung cancer harboring EGFR mutation |
Date of disclosure of the study information | 2011/09/02 |
Last modified on | 2014/09/02 12:49:19 |
A phase I study of pemetrexed and gefitinib in chemotherapy naive elderly patients with non- small cell lung cancer harboring EGFR mutation
A phase I study of pemetrexed and gefitinib in chemotherapy naive elderly patients with non- small cell lung cancer harboring EGFR mutation
A phase I study of pemetrexed and gefitinib in chemotherapy naive elderly patients with non- small cell lung cancer harboring EGFR mutation
A phase I study of pemetrexed and gefitinib in chemotherapy naive elderly patients with non- small cell lung cancer harboring EGFR mutation
Japan |
Non-Small Cell Lung Cancer
Pneumology |
Malignancy
NO
To determine the maximum tolerated dose (MTD) of pemetrexed and gefitinib in chemotherapy naive elderly patients with non- small cell lung cancer harboring EGFR mutation
Safety,Efficacy
Exploratory
Phase I
Maximum tolerated dose (MTD) of pemetrexed and gefitinib
Anti tumor efficacy
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Level 1 gefitinib250mg/day and pemetrexed (300mg/m2)
Level 2 gefitinib250mg/day and pemetrexed (400mg/m2)
Level 3 gefitinib250mg/day and pemetrexed (500mg/m2)
If none of the 3 patients who had been originally allocated to a dosage level experienced
DLT, the dose of pemetrexed was increased to the next level. If one of the 3 patients experienced DLT at that level, 3 additional patients were enrolled for the further evaluation of toxicity. If two of 3 patients experienced DLT at that level, that dose was defined as the MTD.
70 | years-old | <= |
Not applicable |
Male and Female
1)Histology/cytology-proven non-small cell lung cancer, age of 70 years or over
2)NSCLC harboring mutations of EGFR
3)Stage IIIB, IV
4)Chemotherapy naïve patients
5)Performance status(ECOG): 0-1
6)Adequate organ function
7)Written informed consent
1)Serious infections
2)Serious clinical problems
3)Interstitial pneumonia/lung fibrosis on chest CT
4)Active concomitant malignancy
5)Symptomatic brain metastasis
6)Massive pericardial, pleural effusion, ascites
7)Previous drug allergy
8)Those judged to be not suitable by the attending physician
11
1st name | |
Middle name | |
Last name | Masao Ichiki |
National Hospital Organization Kyushu Medical Center
Department of Respiratory Medicine
1-8-1 Jigyohama Chuo-ku, Fukuoka 810-8563, Japan
092-852-0700
ichiki@kyumed.jp
1st name | |
Middle name | |
Last name | Masao Ichiki |
National Hospital Organization Kyushu Medical Center
Department of Respiratory Medicine
1-8-1 Jigyohama Chuo-ku, Fukuoka 810-8563, Japan
092-852-0700
ichiki@kyumed.jp
National Hospital Organization Kyushu Medical Center
Department of Respiratory Medicine
National Hospital Organization Kyushu Medical Center
Department of Respiratory Medicine
Other
NO
2011 | Year | 09 | Month | 02 | Day |
Unpublished
Completed
2010 | Year | 09 | Month | 27 | Day |
2011 | Year | 09 | Month | 01 | Day |
2015 | Year | 03 | Month | 30 | Day |
2015 | Year | 09 | Month | 02 | Day |
2015 | Year | 03 | Month | 30 | Day |
2011 | Year | 09 | Month | 02 | Day |
2014 | Year | 09 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007427